Clinical outcomes of pembrolizumab therapy in advanced‐NSCLC patients with poor performance status (≥3) and high PD‐L1 expression (TPS ≥50%): A case series

Pembrolizumab is the standard first‐line treatment for advanced non‐small cell lung cancer (NSCLC) with programmed death‐ligand 1 (PD‐L1) expression tumor proportion score (TPS) ≥50%. The benefit of pembrolizumab in patients with advanced NSCLC and poor performance status (PS ≥3) is limited, even wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Inaba‐Higashiyama, Ryoko, Yoshida, Tatsuya, Jo, Hitomi, Shirasawa, Masayuki, Motoi, Noriko, Ohe, Yuichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7705620/
https://www.ncbi.nlm.nih.gov/pubmed/33085191
http://dx.doi.org/10.1111/1759-7714.13713

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7705620/
https://www.ncbi.nlm.nih.gov/pubmed/33085191
http://dx.doi.org/10.1111/1759-7714.13713

Ejemplares similares